Top

Published in:

01-03-2018

MiR-181 family-specific behavior in different cancers: a meta-analysis view

Authors: Cecilia Pop-Bica, Sebastian Pintea, Roxana Cojocneanu-Petric, Giannino Del Sal, Silvano Piazza, Zhao-Hui Wu, Alvaro J. Alencar, Izidore S. Lossos, Ioana Berindan-Neagoe, George A. Calin

Published in: Cancer and Metastasis Reviews | Issue 1/2018

Abstract

The involvement of microRNAs in malignant transformation and cancer progression was previously grounded. The observations made by multiple published studies led to the conclusion that some of these small sequences could be eventually used as biomarkers for diagnosis/prognosis. This meta-analysis investigated whether microRNA-181 family members could predict the outcome of patients carrying different types of cancer. We searched the PubMed and Embase databases for studies evaluating the expression levels of miR-181a/b/c/d in patients with cancer, selecting the publications that assessed the relation between low and high levels of one of these four microRNAs and patients’ outcome. Hazard ratios (HRs) or risk ratios (RRs) were extracted from the studies, and random-effect model was performed to investigate the role of miR-181 in the outcome of these patients. The meta-analysis comprised 26 studies including 2653 cancer patients from 6 countries. The results showed significant association between the expression of miR-181 family members and colorectal cancer. Considering the heterogeneity of the pathologies, the analysis, including all types of cancer and the expression of all the miR-181 family members together, showed no association with distinct outcome (HR = 1.099, p = 0.435). When the analysis was performed on each microRNA separately, the expression of miR-181c was significantly associated with the outcome of patients with cancer (HR = 2.356, p = 0.011) and miR-181a expression levels significantly correlated with survival in patients with non-small-cell lung cancer (HR = 0.177, p < 0.05). This meta-analysis revealed evidence regarding the involvement of miR-181 family members in the outcome of patients with some types of cancer, according to their expression level.

Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433(7027), 769–773. https://doi.org/10.1038/nature03315.CrossRefPubMed

Gottardo, F., Liu, C. G., Ferracin, M., Calin, G. A., Fassan, M., Bassi, P., et al. (2007). Micro-RNA profiling in kidney and bladder cancers. Urologic Oncology, 25(5), 387–392. https://doi.org/10.1016/j.urolonc.2007.01.019.CrossRefPubMed

Croce, C. M., & Calin, G. A. (2005). miRNAs, cancer, and stem cell division. Cell, 122(1), 6–7. https://doi.org/10.1016/j.cell.2005.06.036.CrossRefPubMed

Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 101(9), 2999–3004. https://doi.org/10.1073/pnas.0307323101.CrossRefPubMedPubMedCentral

Xi, X., Li, T., Huang, Y., Sun, J., Zhu, Y., Yang, Y., et al. (2017). RNA biomarkers: frontier of precision medicine for cancer. Non-Coding RNA, 3(1), 9.CrossRef

Chen, C. Z., Li, L., Lodish, H. F., & Bartel, D. P. (2004). MicroRNAs modulate hematopoietic lineage differentiation. Science, 303(5654), 83–86. https://doi.org/10.1126/science.1091903.CrossRefPubMed

Cichocki, F., Felices, M., McCullar, V., Presnell, S. R., Al-Attar, A., Lutz, C. T., et al. (2011). Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. Journal of Immunology, 187(12), 6171–6175. https://doi.org/10.4049/jimmunol.1100835.CrossRef

Li, X., Zhang, J., Gao, L., McClellan, S., Finan, M. A., Butler, T. W., et al. (2012). MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death and Differentiation, 19(3), 378–386. https://doi.org/10.1038/cdd.2011.127.CrossRefPubMed

Sun, X., Icli, B., Wara, A. K., Belkin, N., He, S., Kobzik, L., et al. (2012). MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. The Journal of Clinical Investigation, 122(6), 1973–1990. https://doi.org/10.1172/JCI61495.PubMedPubMedCentral

10.

Kozloski, G. A., Jiang, X., Bhatt, S., Ruiz, J., Vega, F., Shaknovich, R., et al. (2016). MiR-181a negatively regulates NF-kappaB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis. Blood. https://doi.org/10.1182/blood-2015-11-680462.

11.

Lwin, T., Lin, J., Choi, Y. S., Zhang, X., Moscinski, L. C., Wright, K. L., et al. (2010). Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood, 116(24), 5228–5236. https://doi.org/10.1182/blood-2010-03-275925.CrossRefPubMedPubMedCentral

12.

Wang, H., Tao, T., Yan, W., Feng, Y., Wang, Y., Cai, J., et al. (2015). Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma. Scientific Reports, 5, 13072. https://doi.org/10.1038/srep13072.CrossRefPubMedPubMedCentral

13.

Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2257–2261. https://doi.org/10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral

14.

Bisso, A., Faleschini, M., Zampa, F., Capaci, V., De Santa, J., Santarpia, L., et al. (2013). Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 12(11), 1679–1687. https://doi.org/10.4161/cc.24757.CrossRefPubMedPubMedCentral

15.

Sun, X., Charbonneau, C., Wei, L., Chen, Q., & Terek, R. M. (2015). miR-181a targets RGS16 to promote chondrosarcoma growth, angiogenesis, and metastasis. Molecular Cancer Research, 13(9), 1347–1357. https://doi.org/10.1158/1541-7786.MCR-14-0697.CrossRefPubMedPubMedCentral

16.

Pichiorri, F., Suh, S. S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., et al. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 12885–12890. https://doi.org/10.1073/pnas.0806202105.CrossRefPubMedPubMedCentral

17.

Xi, Y., Formentini, A., Chien, M., Weir, D. B., Russo, J. J., Ju, J., et al. (2006). Prognostic values of microRNAs in colorectal cancer. Biomarker Insights, 2, 113–121.PubMed

18.

Sochor, M., Basova, P., Pesta, M., Dusilkova, N., Bartos, J., Burda, P., et al. (2014). Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer, 14, 448. https://doi.org/10.1186/1471-2407-14-448.CrossRefPubMedPubMedCentral

19.

Ciafre, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C. G., Sabatino, G., et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 334(4), 1351–1358. https://doi.org/10.1016/j.bbrc.2005.07.030.CrossRefPubMed

20.

Wang, X. F., Shi, Z. M., Wang, X. R., Cao, L., Wang, Y. Y., Zhang, J. X., et al. (2012). MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. Journal of Cancer Research and Clinical Oncology, 138(4), 573–584. https://doi.org/10.1007/s00432-011-1114-x.CrossRefPubMed

21.

Li, Z., Huang, H., Li, Y., Jiang, X., Chen, P., Arnovitz, S., et al. (2012). Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood, 119(10), 2314–2324. https://doi.org/10.1182/blood-2011-10-386235.CrossRefPubMedPubMedCentral

22.

Xiang, L., Li, M., Liu, Y., Cen, J., Chen, Z., Zhen, X., et al. (2013). The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Annals of Hematology, 92(8), 1063–1069. https://doi.org/10.1007/s00277-013-1729-x.CrossRefPubMed

23.

Rossi, S., Shimizu, M., Barbarotto, E., Nicoloso, M. S., Dimitri, F., Sampath, D., et al. (2010). microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 116(6), 945–952. https://doi.org/10.1182/blood-2010-01-263889.CrossRefPubMedPubMedCentral

24.

Schwind, S., Maharry, K., Radmacher, M. D., Mrozek, K., Holland, K. B., Margeson, D., et al. (2010). Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology, 28(36), 5257–5264. https://doi.org/10.1200/JCO.2010.29.2953.CrossRefPubMedPubMedCentral

25.

Zhi, F., Chen, X., Wang, S., Xia, X., Shi, Y., Guan, W., et al. (2010). The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. European Journal of Cancer, 46(9), 1640–1649. https://doi.org/10.1016/j.ejca.2010.02.003.CrossRefPubMed

26.

Ota, D., Mimori, K., Yokobori, T., Iwatsuki, M., Kataoka, A., Masuda, N., et al. (2011). Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. International Journal of Oncology, 38(4), 955–962. https://doi.org/10.3892/ijo.2011.926.PubMed

27.

Bovell, L. C., Shanmugam, C., Putcha, B. D., Katkoori, V. R., Zhang, B., Bae, S., et al. (2013). The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clinical Cancer Research, 19(14), 3955–3965. https://doi.org/10.1158/1078-0432.CCR-12-3302.CrossRefPubMedPubMedCentral

28.

Nishimura, J., Handa, R., Yamamoto, H., Tanaka, F., Shibata, K., Mimori, K., et al. (2012). microRNA-181a is associated with poor prognosis of colorectal cancer. Oncology Reports, 28(6), 2221–2226. https://doi.org/10.3892/or.2012.2059.CrossRefPubMed

29.

Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., et al. (2011). MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clinical Cancer Research, 17(12), 4125–4135. https://doi.org/10.1158/1078-0432.CCR-11-0224.CrossRefPubMedPubMedCentral

30.

Jiang, J., Zheng, X., Xu, X., Zhou, Q., Yan, H., Zhang, X., et al. (2011). Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. PLoS One, 6(8), e23271. https://doi.org/10.1371/journal.pone.0023271.CrossRefPubMedPubMedCentral

31.

Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., et al. (2012). miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology, 14(6), 712–719. https://doi.org/10.1093/neuonc/nos089.CrossRefPubMedPubMedCentral

32.

Gao, W., Yu, Y., Cao, H., Shen, H., Li, X., Pan, S., et al. (2010). Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomedicine & Pharmacotherapy, 64(6), 399–408. https://doi.org/10.1016/j.biopha.2010.01.018.CrossRef

33.

Wang, X., Chen, X., Meng, Q., Jing, H., Lu, H., Yang, Y., et al. (2015). MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFbetaR1/Smad signaling pathway in NSCLC. Scientific Reports, 5, 17618. https://doi.org/10.1038/srep17618.CrossRefPubMedPubMedCentral

34.

Chen, M., Wang, M., Xu, S., Guo, X., & Jiang, J. (2015). Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget, 6(42), 44466–44479. https://doi.org/10.18632/oncotarget.6298.CrossRefPubMedPubMedCentral

35.

Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., et al. (2014). microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature Communications, 5, 2977. https://doi.org/10.1038/ncomms3977.CrossRefPubMedPubMedCentral

36.

Petrillo, M., Zannoni, G. F., Beltrame, L., Martinelli, E., DiFeo, A., Paracchini, L., et al. (2016). Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology, 27(4), 625–634. https://doi.org/10.1093/annonc/mdw007.CrossRefPubMed

37.

Severino, P., Oliveira, L. S., Andreghetto, F. M., Torres, N., Curioni, O., Cury, P. M., et al. (2015). Small RNAs in metastatic and non-metastatic oral squamous cell carcinoma. BMC Medical Genomics, 8, 31. https://doi.org/10.1186/s12920-015-0102-4.CrossRefPubMedPubMedCentral

38.

Yang, C. C., Hung, P. S., Wang, P. W., Liu, C. J., Chu, T. H., Cheng, H. W., et al. (2011). miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. Journal of Oral Pathology & Medicine, 40(5), 397–404. https://doi.org/10.1111/j.1600-0714.2010.01003.x.CrossRef

39.

Cao, Y., Zhao, D., Li, P., Wang, L., Qiao, B., Qin, X., et al. (2017). MicroRNA-181a-5p impedes IL-17-induced nonsmall cell lung cancer proliferation and migration through targeting VCAM-1. Cellular Physiology and Biochemistry, 42(1), 346–356. https://doi.org/10.1159/000477389.CrossRefPubMed

40.

Peng, W., Si, S., Zhang, Q., Li, C., Zhao, F., Wang, F., et al. (2015). Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression. Journal of Experimental & Clinical Cancer Research, 34, 79. https://doi.org/10.1186/s13046-015-0197-7.CrossRef

41.

Neel, J. C., & Lebrun, J. J. (2013). Activin and TGFbeta regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Cellular Signalling, 25(7), 1556–1566. https://doi.org/10.1016/j.cellsig.2013.03.013.CrossRefPubMed

42.

Kastrati, I., Canestrari, E., & Frasor, J. (2015). PHLDA1 expression is controlled by an estrogen receptor-NFkappaB-miR-181 regulatory loop and is essential for formation of ER+ mammospheres. Oncogene, 34(18), 2309–2316. https://doi.org/10.1038/onc.2014.180.CrossRefPubMed

43.

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology, 62(10), 1006–1012. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRefPubMed

44.

Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016). Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology, 2(12), 1607–1616. https://doi.org/10.1001/jamaoncol.2016.2453.CrossRefPubMed

45.

Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis: John Wiley & Sons, Ltd.

46.

Card, N. A. (2012). Applied meta-analysis for social science research. New York: Guilford Prese.

47.

Kepes, S., Banks, G. C., McDaniel, M., & Whetzel, D. L. (2012). Publication bias in the organizational sciences. Organizational Research Methods, 15(4), 624–662. https://doi.org/10.1177/1094428112452760.CrossRef

48.

Ge, Y. Z., Xu, L. W., Xu, Z., Wu, R., Xin, H., Zhu, M., et al. (2015). Expression profiles and clinical significance of microRNAs in papillary renal cell carcinoma: a STROBE-compliant observational study. Medicine (Baltimore), 94(16), e767. https://doi.org/10.1097/MD.0000000000000767.CrossRef

49.

Lee, H., Park, C. S., Deftereos, G., Morihara, J., Stern, J. E., Hawes, S. E., et al. (2012). MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World Journal of Surgical Oncology, 10, 174. https://doi.org/10.1186/1477-7819-10-174.CrossRefPubMedPubMedCentral

50.

Yamazaki, N., Koga, Y., Taniguchi, H., Kojima, M., Kanemitsu, Y., Saito, N., et al. (2017). High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget, 8(4), 6970–6983. https://doi.org/10.18632/oncotarget.14344.CrossRefPubMed

51.

Smid, D., Kulda, V., Srbecka, K., Kubackova, D., Dolezal, J., Daum, O., et al. (2016). Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. International Journal of Oncology, 48(6), 2693–2703. https://doi.org/10.3892/ijo.2016.3484.CrossRefPubMed

52.

Wang, Y., Li, Z., He, C., Wang, D., Yuan, X., Chen, J., et al. (2010). MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells, Molecules & Diseases, 44(3), 191–197. https://doi.org/10.1016/j.bcmd.2009.12.010.CrossRef

53.

Yang, J., Liu, H., Wang, H., & Sun, Y. (2013). Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer. Pathology, Research and Practice, 209(8), 490–494. https://doi.org/10.1016/j.prp.2013.04.018.CrossRefPubMed

54.

Nishida, N., Arizumi, T., Hagiwara, S., Ida, H., Sakurai, T., & Kudo, M. (2017). MicroRNAs for the prediction of early response to sorafenib treatment in human hepatocellular carcinoma. Liver Cancer, 6(2), 113–125. https://doi.org/10.1159/000449475.CrossRefPubMed

55.

Niu, J., Xue, A., Chi, Y., Xue, J., Wang, W., Zhao, Z., et al. (2016). Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene, 35(10), 1302–1313. https://doi.org/10.1038/onc.2015.189.CrossRefPubMed

56.

Smith, B. N., Burton, L. J., Henderson, V., Randle, D. D., Morton, D. J., Smith, B. A., et al. (2014). Snail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2. PLoS One, 9(8), e104987. https://doi.org/10.1371/journal.pone.0104987.CrossRefPubMedPubMedCentral

57.

Yang, Z., Zhang, B., Liu, B., Xie, Y., & Cao, X. (2015). Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer. Tumour Biology, 36(6), 4565–4573. https://doi.org/10.1007/s13277-015-3101-3.CrossRefPubMed

58.

He, X., Liu, Z., Peng, Y., & Yu, C. (2016). MicroRNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-beta pathway. Biochemical and Biophysical Research Communications, 469(4), 1041–1048. https://doi.org/10.1016/j.bbrc.2015.12.021.CrossRefPubMed

59.

Zhu, D. X., Miao, K. R., Fang, C., Fan, L., Zhu, W., Zhu, H. Y., et al. (2011). Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. Leukemia Research, 35(6), 730–734. https://doi.org/10.1016/j.leukres.2010.11.005.CrossRefPubMed

60.

Zhu, D. X., Zhu, W., Fang, C., Fan, L., Zou, Z. J., Wang, Y. H., et al. (2012). miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis, 33(7), 1294–1301. https://doi.org/10.1093/carcin/bgs179.CrossRefPubMed

61.

Li, H., Zhang, P., Sun, X., Sun, Y., Shi, C., Liu, H., et al. (2015). MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells. International Journal of Oncology, 47(4), 1379–1392. https://doi.org/10.3892/ijo.2015.3144.CrossRefPubMed

62.

Li, X., Han, J., Zhu, H., Peng, L., & Chen, Z. (2017). miR181b5p mediates TGFbeta1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells. International Journal of Oncology, 51(1), 158–168. https://doi.org/10.3892/ijo.2017.4007.CrossRefPubMedPubMedCentral

63.

Zhang, X., Li, X., Tan, F., Yu, N., & Pei, H. (2017). STAT1 inhibits miR-181a expression to suppress colorectal cancer cell proliferation through PTEN/Akt. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.26000.

64.

Liu, Y., Uzair Ur, R., Guo, Y., Liang, H., Cheng, R., Yang, F., et al. (2016). miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4. Protein & Cell, 7(10), 722–734. https://doi.org/10.1007/s13238-016-0313-2.CrossRef

65.

Ji, D., Chen, Z., Li, M., Zhan, T., Yao, Y., Zhang, Z., et al. (2014). MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Molecular Cancer, 13, 86. https://doi.org/10.1186/1476-4598-13-86.CrossRefPubMedPubMedCentral

66.

Yoo, J. O., Kwak, S. Y., An, H. J., Bae, I. H., Park, M. J., & Han, Y. H. (2016). miR-181b-3p promotes epithelial-mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. Biochimica et Biophysica Acta, 1863(7 Pt A), 1601–1611. https://doi.org/10.1016/j.bbamcr.2016.04.016.CrossRefPubMed

67.

Zhao, L., Li, Y., Song, X., Zhou, H., Li, N., Miao, Y., et al. (2016). Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia. Oncotarget, 7(37), 60074–60086. https://doi.org/10.18632/oncotarget.11054.PubMedPubMedCentral

68.

Gupta, A., Sharma, A., Yadav, A., Rastogi, N., Agrawal, S., Kumar, A., et al. (2015). Evaluation of miR-27a, miR-181a, and miR-570 genetic variants with gallbladder cancer susceptibility and treatment outcome in a North Indian population. Molecular Diagnosis & Therapy, 19(5), 317–327. https://doi.org/10.1007/s40291-015-0159-y.CrossRef

69.

Lin, S., Pan, L., Guo, S., Wu, J., Jin, L., Wang, J. C., et al. (2013). Prognostic role of microRNA-181a/b in hematological malignancies: a meta-analysis. PLoS One, 8(3), e59532. https://doi.org/10.1371/journal.pone.0059532.CrossRefPubMedPubMedCentral

Title: MiR-181 family-specific behavior in different cancers: a meta-analysis view
Authors: Cecilia Pop-Bica
Sebastian Pintea
Roxana Cojocneanu-Petric
Giannino Del Sal
Silvano Piazza
Zhao-Hui Wu
Alvaro J. Alencar
Izidore S. Lossos
Ioana Berindan-Neagoe
George A. Calin
Publication date: 01-03-2018
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-017-9714-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Mutations of key driver genes in colorectal cancer progression and metastasis

MicroRNAs and metastasis: small RNAs play big roles

From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer

Non-coding RNAs, epigenetics, and cancer: tying it all together

Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

Long non-coding RNAs in metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer